dr peter attia semaglutide New insights on GLP-1 agonists—Ozempic, Wegovy, Mounjaro, and more (AMA 64 sneak peek) Dr. Peter Attia on The

Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness

Fat loss effects accumulate over the full cycle length

Taking Sermorelin in the evening may help maximize its effectiveness and support better sleep quality

J., Zajac, J

PAD is associated with a 3-4x increased risk of cardiovascular events

These 3.8 million met the clinical criteria for the Bridge program, did not have a diagnosis of type 2 diabetes, sleep apnea or MASH, did not have a GLP-1 Part D covered prescription in 2023 and "could be eligible for the Medicare GLP-1 Bridge, assuming no changes in diagnosis or GLP-1 use in Part D in 2026," the report added